Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Background: EGFR L858R mutation is associated with poorer efficacy of EGFR-tyrosine kinase inhibitors (TKIs) than EGFR Ex19del in patients with non-small cell lung cancer (NSCLC). However, ramucirumab (RAM) + erlotinib (ERL) therapy exhibited comparable efficacy between patients with L858R mutation...

Full description

Saved in:
Bibliographic Details
Main Authors: Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, Yuki Takeyasu, Yukihiro Hasegawa, Yuki Sato, Yoshiki Negi, Tomohiro Oba, Toshiyuki Sumi, Hirokuni Hirata, Hidemitsu Funabashi, Yuko Oya, Hajime Kikuchi, Naoko Katsurada, Takeshi Nakatani, Keiko Tanimura, Taku Nakagawa, Naoya Takeda, Takahiro Asami, Osamu Honjo, Hiromi Nagashima, Takumi Yamaura, Norihiko Hata, Miyako Kitazono, Naoya Nishioka, Akihiro Tamiya, Yuichi Sakamori, Ryota Shigaki, Kyoichi Kaira, Ryoichi Honda, Takashi Matsui, Eriko Suzuki, Kentaro Ito, Kojiro Otsuka, Naoto Takase, Yusuke Murakami, Kazuhiko Matsuno, Sumito Inoue, Akira Kisohara, Sojiro Kusumoto, Hiroe Aoshima, Yumiko Kakizaki, Akihito Kubo, Akito Hata, Nobuhisa Ishikawa, Kosuke Hamai, Nobuhiro Kanaji, Toshihiro Misumi, Noriyuki Matsutani, Nobuhiko Seki
Format: Article
Language:English
Published: SAGE Publishing 2025-06-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251344010
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17588359251344010

Similar Items